期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 109, 期 6, 页码 1528-1537出版社
WILEY
DOI: 10.1002/cpt.2122
关键词
-
资金
- National Science Foundation Graduate Research Fellowship [DGE - 1656518]
- Big Data to Knowledge (BD2K) from the National Institutes of Health [T32 LM012409]
- NIH/National Institute of General Medical Sciences PharmGKB resource [U24HG010615]
- NIH [GM102365]
Pharmacogenetics studies the influence of genetic variation on drug response, finding that the majority of individuals may have atypical responses to at least one drug and on average have atypical responses to 10.3 drugs. Nearly a quarter of participants have been prescribed drugs for which they are predicted to have atypical responses.
Pharmacogenetics (PGx) studies the influence of genetic variation on drug response. Clinically actionable associations inform guidelines created by the Clinical Pharmacogenetics Implementation Consortium (CPIC), but the broad impact of genetic variation on entire populations is not well understood. We analyzed PGx allele and phenotype frequencies for 487,409 participants in the UK Biobank, the largest PGx study to date. For 14 CPIC pharmacogenes known to influence human drug response, we find that 99.5% of individuals may have an atypical response to at least 1 drug; on average they may have an atypical response to 10.3 drugs. Nearly 24% of participants have been prescribed a drug for which they are predicted to have an atypical response. Non-European populations carry a greater frequency of variants that are predicted to be functionally deleterious; many of these are not captured by current PGx allele definitions. Strategies for detecting and interpreting rare variation will be critical for enabling broad application of pharmacogenetics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据